Himuka AM Pharma, a Peptide Drug Developer, Concludes Licensing Agreement
NQ Score
100/100
AI Summary (NQ-processed)
Himuka AM Pharma Co., Ltd. has signed a licensing agreement with Pharma Foods Co., Ltd. for the bioactive peptide "Adrenomedullin" (development code HM101). This agreement grants Pharma Foods exclusive rights for research, development, manufacturing, and sales in Japan, Korea, and Taiwan for the treatment of CADASIL. Adrenomedullin, discovered in 1993, is known for its diverse effects including angiogenesis and anti-inflammatory properties.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What kind of agreement did Himuka AM Pharma Co., Ltd. and Pharma Foods Co., Ltd. conclude?
- A: It is a licensing agreement concerning the bioactive peptide "Adrenomedullin" (development code HM101).
- Q: What is the target disease for the licensing agreement?
- A: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL).